Image: Guido van Nispen [CC BY 2.0], via Flickr
European Commission approves AbbVie’s takeover of Ireland’s Allergan, subject to conditions
The European Commission, in its capacity as enforcer of EU competition law, has approved the proposed takeover of the Ireland-headquartered pharmaceutical company Allergan by United States-based rival AbbVie. According to Allergan, the value of the takeover is about $63 billion (€57bn).
However, the move can only go ahead if Allergan sells a product it is developing to treat inflammatory bowel disease, the Commission said. Both companies are working on artificial antibodies designed to block the action of an inflammatory signalling molecule that has a role in some autoimmune diseases.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.